Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Integrative Genomics of COVID-19 Disease in Vaccination Breakthrough

PROVIDER: PRJNA868733 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21973824_1.fastq.gz	Fastqsanger.gz
	SRR21973824_2.fastq.gz	Fastqsanger.gz
	SRR21973825_1.fastq.gz	Fastqsanger.gz
	SRR21973825_2.fastq.gz	Fastqsanger.gz
	SRR21973826_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 116

Similar Datasets

RNA-seq of PBMCs isolated from patients with various cancers and COVID-19 infection status

Project description:This experiment aims to understand transcriptomic signatures associated with COVID-19 infected individuals with cancer. Samples were taken before the third dose of the COVID-19 mRNA vaccination and examined differences between samples with a breakthrough infection versus without breakthrough infection, as well as subjects with haematological malignancies versus solid tumours. The results found that cancer patients with haematological malignancies are at increased risk of breakthrough infections.

2025-04-17 | E-MTAB-14545 | biostudies-arrayexpress

Complementarity Determining Regions in SARS-CoV-2 hybrid immunity

Project description:Pre-vaccination SARS-CoV-2 infection can boost protection elicited by COVID-19 vaccination and post-vaccination breakthrough SARS-CoV-2 infection can boost existing immunity conferred by COVID-19 vaccination. Such ‘hybrid immunity’ is effective against SARS-CoV-2 variants. In order to understand ‘hybrid immunity’ at the molecular level we studied the complementarity determining regions (CDR) of anti-RBD (receptor binding domain) antibodies isolated from individuals with ‘hybrid immunity’ as well as from ‘naive’ (notSARS-CoV-2 infected) vaccinated individuals. CDR analysis was done by liquid chromatography/mass spectrometry-mass spectrometry.

2023-02-08 | PXD038849 | Pride

Project description:Integrative Genomics of COVID-19 Disease

| PRJNA676016 | ENA

Prior vaccination prevents overactivation of innate immune responses during COVID-19 breakthrough infection

Project description:At this stage in the COVID-19 pandemic, most infections are 'breakthrough' infections that occur in individuals with prior immunity to SARS-CoV-2 through infection or vaccination. Understanding both innate and adaptive immune induction in the setting of breakthrough infection is critical to refining vaccine strategies to ensure long-term efficacy against emerging variants, yet existing studies have primarily focused on adaptive immune responses. Here, we performed single-cell transcriptomic, proteomic, and functional profiling of innate and adaptive immunity during primary and breakthrough COVID-19 infections by comparing immune responses between unvaccinated and vaccinated individuals during the SARS-CoV-2 Delta wave. Breakthrough infections were characterized by a significantly less activated transcriptomic profile in CD56dim NK cells and monocytes, with induction of pathways limiting NK cell proliferation and monocyte migratory potential. Furthermore, we observed a female-specific trend of increased transcriptomic activation of CD16+ monocytes and type-2 conventional dendritic cells (cDC2s) during breakthrough infections. Despite these differences, antibody-dependent cellular cytotoxicity responses were similar between breakthrough and primary infection groups. These insights suggest that prior vaccination prevents overactivation of innate immune responses during breakthrough infections with discernible sex-specific patterns and underscore the potential of harnessing vaccines in mitigating pathologic immune responses resulting from overactivation.

2025-01-30 | GSE261862 | GEO

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease

Project description:COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease

| PRJNA951713 | ENA

Immune transcriptome in adult-onset Still’s disease with mild flare following administration of mRNA vaccine BNT162b2

Project description:Adult-onset Still’s disease (AOSD) patients represent a population for which vaccination can induce disease flare1. The COVID-19 pandemic vaccination programs presented these patients and their health care providers with a critical decision. Previously it has been described that AOSD patients can experience disease flare with COVID-19 vaccination but no one has yet reported their immune transcriptional and antibody response. Here we present the transcriptional response and anti-spike antibody profile of a 58-year-old male after vaccination with BNT162b2 who experienced a mild AOSD flare following the second vaccine.

2022-05-18 | GSE198549 | GEO

Altered expression of PBMC miRNA profile following the third dose of inactivated COVID-19 vaccine

Project description:COVID-19 vaccination is the most effective approach to prevent severe disease and death. Inactivated vaccines are the most accessible type of COVID-19 vaccines in the developing countries. Several studies, including work from our group, have demonstrated that the third (booster) dose of inactivated COVID-19 vaccine induces robust humoral and cellular immune responses. The aim of this study was to examine miRNA expression profile in participants received a homogenous third dose of the CoronaVac vaccine.

2024-04-01 | GSE249050 | GEO

Project description:Integrative Genomics of COVID-19 Disease across different Variant of Concern

| PRJNA952815 | ENA

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [small RNA-Seq]

Project description:COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [small RNA-Seq]

| PRJNA951718 | ENA

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [Illumina RNA-Seq]

Project description:COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [Illumina RNA-Seq]

| PRJNA951716 | ENA